Research Topics
Genomes and Genes | William StohlSummaryAffiliation: University of Southern California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trialWilliam Stohl
Division of Rheumatology, Los Angeles County and University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
Ann Rheum Dis 71:1289-96. 2012..To determine the efficacy and safety of ocrelizumab (OCR) with methotrexate (MTX) in MTX-naive rheumatoid arthritis (RA) patients...
Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?William Stohl
Division of Rheumatology, University of Southern California Keck School of Medicine, 2011 Zonal Avenue, HMR 711, Los Angeles, CA 90033, USA
Curr Rheumatol Rep 14:303-9. 2012..Whether these differences will have meaningful consequences for efficacy and safety remains to be determined...- Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosusWilliam Stohl
Los Angeles County University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
Arthritis Rheum 64:2328-37. 2012.... - The discovery and development of belimumab: the anti-BLyS-lupus connectionWilliam Stohl
Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, California, USA
Nat Biotechnol 30:69-77. 2012.... - Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosusRichard Furie
Division of Rheumatology and Allergy Clinical Immunology, North Shore Long Island Jewish Health System, Marcus Avenue, Lake Success, New York 11042, USA
Arthritis Res Ther 10:R109. 2008.... 
B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observationsWilliam Stohl
Los Angeles County University of Southern California Medical Center, and University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
Arthritis Rheum 48:3475-86. 2003..To assess the overexpression of B lymphocyte stimulator (BLyS) over time in patients with systemic lupus erythematosus (SLE)...- A therapeutic role for BLyS antagonistsW Stohl
Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles 90033, USA
Lupus 13:317-22. 2004..These features collectively point to BLyS as an attractive therapeutic target in human disease... - Dichotomous effects of complete versus partial class II major histocompatibility complex deficiency on circulating autoantibody levels in autoimmune-prone miceWilliam Stohl
Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA 90333, USA
Arthritis Rheum 50:2227-39. 2004..To assess the effects of altered class II major histocompatibility complex (MHCII) expression on circulating autoantibody levels in C57BL/6 (B6) mice congenic for the Sle1 (B6.Sle1 mice) or Nba2 (B6.Nba2 mice) regions... - Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosusW Stohl
Division of Rheumatology, Department of Medicine, Los Angeles County University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
Ann Rheum Dis 63:1096-103. 2004.... - BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonistsWilliam Stohl
Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
Curr Dir Autoimmun 8:289-304. 2005..These features collectively point to BLyS and/or its receptors as attractive therapeutic targets in human SLE... - Humoral autoimmunity in mice overexpressing B cell surface CD19: vital role for MHC class IIWilliam Stohl
Division of Rheumatology and Immunology, Department of Medicine, University of Southern California Keck School of Medicine, 2001 Zonal Avenue HMR 711, Los Angeles, CA 90033, USA
Clin Immunol 116:257-64. 2005..This raises the possibility that MHCII affects B cells in a manner that, at least in part, is independent of helper T cell function... - BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosusWilliam Stohl
Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles 90033, USA
Arthritis Rheum 52:2080-91. 2005..To determine whether overexpression of BAFF can accelerate the development of systemic lupus erythematosus-associated end-organ disease in hosts with an underlying autoimmune diathesis... - Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disordersWilliam Stohl
Division of Rheumatology, University of Southern California Keck School of Medicine, 2011 Zonal Avenue HMR 711, Los Angeles, CA 90033, USA
Expert Opin Ther Targets 8:177-89. 2004..Results from a Phase I clinical trial with a BLyS antagonist in human SLE have shown the antagonist to be biologically active and safe. These features collectively point to BLyS as an attractive therapeutic target in human disease... - MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4)William Stohl
Division of Rheumatology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
Int Immunol 16:895-904. 2004.... - Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseasesWilliam Stohl
Division of Rheumatology, University of Southern California, 2011 Zonal Ave HMR 711, Los Angeles, CA 90033, USA
Endocr Metab Immune Disord Drug Targets 6:351-8. 2006..These features collectively point to BLyS as an attractive therapeutic target in human rheumatic diseases... - Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunityWilliam Stohl
Department of Medicine, Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
J Immunol 181:833-41. 2008..These findings may help explain the limited clinical efficacy appreciated to date of BAFF antagonists in human SLE... - SLE--systemic lupus erythematosus: a BLySful, yet BAFFling, disorderWilliam Stohl
Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
Arthritis Res Ther 5:136-8. 2003.... - Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunityWilliam Stohl
Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
Arthritis Rheum 62:2432-42. 2010..To determine whether overexpression of BAFF can promote systemic lupus erythematosus (SLE)-like autoimmunity in mice that are otherwise autoimmune-resistant... - Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) proteinWilliam Stohl
Division of Rheumatology, University of Southern California, Keck School of Medicine, Los Angeles 90033, USA
Curr Opin Rheumatol 14:522-8. 2002..By inference, BLyS protein may also play an important contributory role in pathogenesis and/or propagation of human SLE and becomes a legitimate candidate target for antagonist biologic agents... - B lymphocyte stimulator protein-associated increase in circulating autoantibody levels may require CD4+ T cells: lessons from HIV-infected patientsWilliam Stohl
Division of Rheumatology, Department of Medicine, Los Angeles County, Los Angeles, CA, USA
Clin Immunol 104:115-22. 2002..This raises the possibility that the combination of a BLyS protein antagonist with an agent that targets (helper) T cells may have salutary synergistic effects on autoantibody production in diseases such as systemic lupus erythematosus... - B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseasesWilliam Stohl
University of Southern California Keck School of Medicine, Division of Rheumatology, 2011 Zonal Avenue HMR 711, Los Angeles, CA 90033, USA
Curr Rheumatol Rep 4:345-50. 2002..In addition, it may play a similar role in other systemic immune-based rheumatic diseases, and becomes a legitimate candidate target for antagonist biologic agents... - B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks?William Stohl
Division of Rheumatology, Department of Medicine, University of Southern California Keck School of Medicine, 2011 Zonal Avenue HMR 711, Los Angeles, CA 90033, USA
Clin Immunol 121:1-12. 2006..Among the systemic immune-based rheumatic disorders, we will focus on rheumatoid arthritis and systemic lupus erythematosus, two disorders for which therapeutic B cell targeting is being intensely investigated... - Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFFChaim O Jacob
Department of Medicine, Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, 2011 Zonal Avenue, Los Angeles, CA 90033, USA
J Immunol 177:2671-80. 2006..These observations may have profound ramifications for the use of BAFF antagonists in human SLE and related diseases... - Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 miceChaim O Jacob
University of Southern California, Keck School of Medicine, Los Angeles, USA
Arthritis Rheum 64:1610-9. 2012..To determine the role of APRIL in the development of systemic lupus erythematosus (SLE) in mice... - Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathwayNoam Jacob
Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
J Immunol 182:2532-41. 2009.... - B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 miceNoam Jacob
Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
J Immunol 186:4984-93. 2011..Moreover, our results document important biological differences between IFN-α-driven and spontaneous natural SLE disease... - Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritisSoon-Min Tan
Los Angeles County + University of Southern California Medical Center, 90033, USA
Arthritis Rheum 48:982-92. 2003..Together, their local production may foster survival and/or expansion of B cells that produce pathogenic autoantibodies and/or promote local T cell activation and consequent joint destruction... - TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cellsSong Guo Zheng
Division of Rheumatology and Immunology, Department of Medicine, University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA
J Immunol 176:3321-9. 2006..Although natural CD4+CD25+ cells develop normally in CTLA-4(-/-) mice, the lack of TGF-beta-induced, peripheral CD4+CD25+ suppressor cells in these mice may contribute to their rapid demise... - In vitro and in vivo T cell oligoclonality following chronic stimulation with staphylococcal superantigensKyoung Soo Kim
University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA
Clin Immunol 108:182-9. 2003..In hosts who have lost tolerance to self Ag, chronic exposure to SAg may preferentially promote expansion of autoreactive T cells and facilitate development of clinical disease... - Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and futureNoam Jacob
Division of Rheumatology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
Autoimmunity 43:84-97. 2010..With these points in mind, this review will focus on the autoantibody-dependent and autoantibody-independent roles for B cells in SLE and on therapeutic approaches that target B cells... - Development of Systemic Lupus Erythematosus in NZM 2328 Mice in the Absence of any Single BAFF ReceptorChaim O Jacob
University of Southern California Keck School of Medicine, Los Angeles
Arthritis Rheum 65:1043-54. 2013..To determine the necessity for any individual BAFF receptor in the development of systemic lupus erythematosus (SLE)... - B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levelsChristopher E Collins
Division of Rheumatology, Department of Medicine, Los Angeles County University of Southern California Medical Center, Los Angeles, CA 90033, USA
Arthritis Res Ther 8:R6. 2006..BLyS mRNA levels may be a helpful biomarker in the clinical monitoring of SLE patients... - Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosusMichelle Petri
Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD 21205, USA
Arthritis Rheum 58:2453-9. 2008..To determine the association of plasma B lymphocyte stimulator (BLyS) levels, immunosuppressive therapy, and other clinical parameters with disease activity in systemic lupus erythematosus (SLE)... - Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort studyNoa Schwartz
Division of Rheumatology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
Arthritis Res Ther 11:R143. 2009..Evidence for the importance of TWEAK in the pathogenesis of lupus nephritis (LN) has been recently introduced. Thus, TWEAK levels may serve as an indication of LN presence and activity... - A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosusDaniel J Wallace
Cedars Sinai Medical Center, University of California, Los Angeles, USA
Arthritis Rheum 61:1168-78. 2009..To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythematosus (SLE)... - Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedsideWilliam Stohl
Division of Rheumatology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA
Curr Opin Rheumatol 23:305-10. 2011..Several agents that target BLyS are in clinical trials now, and we summarize recent results here, with a focus on systemic lupus erythematosus (SLE)... - New and promising treatments for rheumatoid arthritisR John Looney
Division of Allergy, Immunology, and Rheumatology, Department of Medicine, University of Rochester School of Medicine, Rochester, New York, USA
Am J Orthop 36:18-23. 2007 - Superantigen-driven, CD8+ T cell-mediated down-regulation: CD95 (Fas)-dependent down-regulation of human Ig responses despite CD95-independent killing of activated B cellsW Stohl
Department of Medicine, University of Southern California, Los Angeles 90033, USA
J Immunol 161:3292-8. 1998..This finding may help explain why clinical autoimmunity associated with increased titers of autoantibodies is a predominant feature of defects in CD95 or CD95 ligand... - CD95 (Fas)-based, superantigen-dependent, CD4+ T cell-mediated down-regulation of human in vitro immunoglobulin responsesW Stohl
Department of Medicine, University of Southern California, Los Angeles 90033, USA
J Immunol 160:5231-8. 1998..Defects in SAg-based down-regulation may contribute to autoimmune disorders such as SLE... - In vivo staphylococcal superantigen-driven polyclonal Ig responses in mice: dependence upon CD4(+) cells and human MHC class IIW Stohl
Division of Rheumatology and Immunology, Keck School of Medicine, University of Southern California, 2011 Zonal Avenue, HMR 711, Los Angeles, CA 90033, USA
Int Immunol 13:1291-300. 2001..This model system may be useful in investigating the polyclonally activating effects of microbial products (prototypic environmental insults) on the development of systemic autoimmunity... - BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitisXiaohui Zhou
Division of Rheumatology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, United States of America
PLoS ONE 6:e23629. 2011..BAFF, in addition to promoting B cell survival and differentiation, may affect T cells. The objective of this study was to determine the effect of BAFF on Th17 cell generation and its ramifications for the Th17 cell-driven disease, EAE... - Induced T regulatory cells suppress osteoclastogenesis and bone erosion in collagen-induced arthritis better than natural T regulatory cellsNing Kong
Rheumatology Division, University of Southern California, Los Angeles, California 90033, USA
Ann Rheum Dis 71:1567-72. 2012..Although natural regulatory T cells (nTregs) can suppress osteoclastogenesis, the role of TGF-β-induced CD4+Foxp3+ Tregs (iTregs) in osteoclastogenesis remains unknown... - B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patientsSandy D Hong
Childrens Hospital Los Angeles, Los Angeles, CA 90033, USA
Arthritis Rheum 60:3400-9. 2009..To assess the expression of B lymphocyte stimulator (BLyS) in patients with pediatric systemic lupus erythematosus (SLE) or juvenile idiopathic arthritis (JIA)... - Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseasesG S Cheema
Los Angeles County + University of Southern California Medical Center, University of Southern California, 90033, USA
Arthritis Rheum 44:1313-9. 2001..Local production of BLyS in the joints may contribute to joint pathology. Patients with elevated serum BLyS levels may be ideal candidates for therapeutic targeting of BLyS... - Cytokine disturbances in systemic lupus erythematosusNoam Jacob
Division of Rheumatology, Department of Medicine, University of Southern California Keck School of Medicine, 2011 Zonal Ave, HMR 711, Los Angeles, CA 90033, USA
Arthritis Res Ther 13:228. 2011..The present review will examine the roles of each of these cytokines in murine and human SLE, and will summarize results from clinical trials of agents that target these cytokines... - Increased CXCL8 (IL-8) expression in Multiple SclerosisBrett T Lund
Department of Neurology, Keck School of Medicine, University of Southern California, MCH 142, Los Angeles, California 90033, USA
J Neuroimmunol 155:161-71. 2004..We suggest that CXCL8 may serve as a marker of monocyte activity in MS and may play a role in monocyte recruitment to the CNS... - Elevated synovial expression of triggering receptor expressed on myeloid cells 1 in patients with septic arthritis or rheumatoid arthritisC E Collins
Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
Ann Rheum Dis 68:1768-74. 2009..To determine whether synovial expression of triggering receptor expressed on myeloid cells 1 (TREM-1) is upregulated in patients with distinct types of inflammatory or non-inflammatory arthritis... - Cell cycle phase-specific survival of CD95 ligand-challenged Jurkat cells: upregulation of heat-shock responseT B Parr
Division of Rheumatology and Immunology, Department of Medicine, Keck School of Medicine, University of California, Los Angeles, 90033, USA
Cell Immunol 211:21-9. 2001.... - B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical respondersD T La
Division of Rheumatology, Department of Medicine, Los Angeles County and University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California, USA
Ann Rheum Dis 67:1132-8. 2008..To assess the effects of tumour necrosis factor (TNF) antagonist therapy on B lymphocyte stimulator (BLyS) expression in patients with rheumatoid arthritis (RA)... - BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseasesViktor Roschke
Department of Antibody Development, Human Genome Sciences, 9410 Key West Avenue, Rockville, MD 20850, USA
J Immunol 169:4314-21. 2002..These findings raise the possibility that active BLyS/APRIL heterotrimers may play a role in rheumatic and other autoimmune diseases and that other members of the TNF ligand superfamily may also form active soluble heterotrimers... - Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapseGeraldine Cambridge
University College London, London, UK
Arthritis Rheum 54:723-32. 2006.... - Patients with inflammatory arthritic diseases harbor elevated serum and synovial fluid levels of free and immune-complexed glucose-6-phosphate isomerase (G6PI)Monica Schaller
Department of Immunology, IMM2, The Scripps Research Institute, La Jolla, CA 92037, USA
Biochem Biophys Res Commun 349:838-45. 2006..This, in turn, may trigger production of proinflammatory cytokines and perpetuate the inflammatory process...
Research Grants
- The vital role of BAFF in the development of SLEWilliam Stohl; Fiscal Year: 2007....
- The vital role of BAFF in the development of SLEWilliam Stohl; Fiscal Year: 2010..abstract_text> ..